Loading stock data…
IFRX
$1.67-0.05 (-2.63%)
Market OpenUpdated 3:59 PM EDT
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InflaRx N.V. in the Healthcare sector is trading at $1.67. Wall Street consensus targets $7.87 (7 analysts), implying a +372.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $2.95, remaining 26.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +372.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.67
Potential Downside
0%
Whystock Fair Value$1.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-116.32%
Volume
Today's trading volume
2.08M
Recent News
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in […]
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Izicopan positioned as a next-generation C5
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement […]
April 2026 Penny Stocks To Watch For Potential Growth
The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability...
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]